Guardant Health, Inc. (NASDAQ:GH - Get Free Report) insider Terilyn Monroe sold 3,842 shares of the business's stock in a transaction dated Wednesday, November 18th. The shares were sold at an average price of $142.41, for a total value of $547,139.22. Following the completion of the transaction, the insider directly owned 21,058 shares of the company's stock, valued at approximately $2,998,869.78. This trade represents a 15.43% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Guardant Health Stock Performance
Guardant Health stock traded up $0.45 during midday trading on Thursday, hitting $145.59. 1,869,930 shares of the company were exchanged, compared to its average volume of 2,212,812. The business has a fifty day simple moving average of $167.58 and a two-hundred day simple moving average of $133.48. The firm has a market capitalization of $19.70 billion, a PE ratio of -39.56 and a beta of 1.67. Guardant Health, Inc. has a fifty-two week low of $74.55 and a fifty-two week high of $191.05.
Guardant Health (NASDAQ:GH - Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.46. The firm had revenue of $360.98 million during the quarter, compared to analyst estimates of $350.72 million. The business's revenue for the quarter was up 36.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.74) earnings per share. As a group, equities analysts expect that Guardant Health, Inc. will post -3.28 earnings per share for the current year.
Analyst Upgrades and Downgrades
Several analysts have recently weighed in on GH shares. Royal Bank Of Canada increased their price target on shares of Guardant Health from $185.00 to $200.00 and gave the company an "outperform" rating in a research note on Friday, July 31st. Piper Sandler lowered their price objective on Guardant Health from $193.00 to $190.00 and set an "overweight" rating for the company in a research report on Tuesday, November 10th. TD Cowen reissued a "buy" rating on shares of Guardant Health in a research note on Wednesday. UBS Group lifted their target price on Guardant Health from $175.00 to $225.00 and gave the company a "buy" rating in a research report on Wednesday, September 9th. Finally, The Goldman Sachs Group reaffirmed a "buy" rating and issued a $210.00 price target on shares of Guardant Health in a research note on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $190.88.
Read Our Latest Stock Analysis on GH
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently made changes to their positions in the business. Kestra Advisory Services LLC acquired a new position in shares of Guardant Health during the third quarter worth $479,000. Advisors Asset Management Inc. acquired a new stake in Guardant Health in the third quarter valued at $550,000. Coastal Bridge Advisors LLC lifted its holdings in Guardant Health by 30.4% during the 3rd quarter. Coastal Bridge Advisors LLC now owns 1,766 shares of the company's stock worth $315,000 after buying an additional 412 shares during the last quarter. Integrated Wealth Concepts LLC lifted its holdings in Guardant Health by 10.6% during the 3rd quarter. Integrated Wealth Concepts LLC now owns 7,182 shares of the company's stock worth $1,281,000 after buying an additional 689 shares during the last quarter. Finally, Groupama Asset Managment purchased a new stake in Guardant Health during the 3rd quarter worth about $2,764,000. Hedge funds and other institutional investors own 92.60% of the company's stock.
About Guardant Health
(
Get Free Report)
Guardant Health is a precision oncology company that develops blood- and tissue-based tests to help guide cancer care. Founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz, the company focuses on using genomic information to support cancer detection, treatment selection and disease monitoring. Its products include Guardant360 tests, which analyze tumor-related genetic changes to help inform treatment decisions, and Guardant Reveal, which is designed to detect residual or recurring cancer after treatment.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Guardant Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Guardant Health wasn't on the list.
While Guardant Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.